AR107529A1 - Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento - Google Patents

Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento

Info

Publication number
AR107529A1
AR107529A1 ARP170100274A ARP170100274A AR107529A1 AR 107529 A1 AR107529 A1 AR 107529A1 AR P170100274 A ARP170100274 A AR P170100274A AR P170100274 A ARP170100274 A AR P170100274A AR 107529 A1 AR107529 A1 AR 107529A1
Authority
AR
Argentina
Prior art keywords
compounds
methods
treatment
stratification
compositions
Prior art date
Application number
ARP170100274A
Other languages
English (en)
Inventor
Xiaoyun Wu
Timothy A Lewis
Alex Burgin
Monica Schenone
Waal Luc De
Matthew Meyerson
Heidi Greulich
Lange Martin Dr
Sack Ulrike Dr
Lienau Philip Dr
Eis Knut Dr
Wengner Antje Margret Dr
Original Assignee
Bayer Pharma AG
Broad Inst Inc
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Broad Inst Inc, Dana Farber Cancer Inst Inc filed Critical Bayer Pharma AG
Publication of AR107529A1 publication Critical patent/AR107529A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compuestos mejorados, especialmente de fórmula (1), métodos para identificar pacientes que padecen de cáncer usando biomarcadores (por ejemplo, PDE3A, SLFN12 y/o CREB3L1) que están correlacionados con la sensibilidad al fármaco, y para someter la población de pacientes estratificados al tratamiento correspondiente con un agente de la presente (por ejemplo los compuestos 1 - 6 descriptos en la presente).
ARP170100274A 2016-02-05 2017-02-03 Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento AR107529A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662291935P 2016-02-05 2016-02-05

Publications (1)

Publication Number Publication Date
AR107529A1 true AR107529A1 (es) 2018-05-09

Family

ID=58009797

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100274A AR107529A1 (es) 2016-02-05 2017-02-03 Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento

Country Status (9)

Country Link
US (2) US10966986B2 (es)
EP (1) EP3411037B1 (es)
JP (1) JP7148403B2 (es)
CN (2) CN114601837A (es)
AR (1) AR107529A1 (es)
CA (2) CA3234176A1 (es)
TW (1) TW201733591A (es)
UY (1) UY37113A (es)
WO (1) WO2017134231A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3334404A4 (en) * 2015-08-13 2019-02-13 The Broad Institute, Inc. COMPOSITIONS AND METHODS FOR DETECTION OF CANCER CELLS EXPRESSING PDE3A OR SLFN12
EP3411037B1 (en) * 2016-02-05 2021-10-20 Bayer Pharma Aktiengesellschaft Compounds, compositions and methods for cancer patient stratification and cancer treatment
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2018141835A1 (en) * 2017-02-03 2018-08-09 The Broad Institute, Inc. Compounds, compositions and methods for cancer treatment
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
EP3661917B1 (en) 2017-08-04 2022-05-11 Bayer Aktiengesellschaft 6-((3-trifluoromethyl)phenyl)-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer
JP7104588B2 (ja) * 2017-09-01 2022-07-21 大塚製薬株式会社 ５－メチル－６－フェニル－４，５－ジヒドロ－２ｈ－ピリダジン－３－オン誘導体を含有する悪性腫瘍治療剤
JP7313614B2 (ja) * 2018-04-16 2023-07-25 学校法人順天堂 骨髄増殖性腫瘍の診断
WO2020157199A1 (en) * 2019-02-01 2020-08-06 Bayer Aktiengesellschaft Annulated dihydropyridazinone compounds as anti-cancer compounds
WO2020157236A1 (en) * 2019-02-01 2020-08-06 Bayer Aktiengesellschaft Pyridyl substituted dihydrooxadiazinones
CN110894529A (zh) * 2019-12-16 2020-03-20 新乡医学院 一种与结直肠癌早期诊断相关的环状rna标志物、检测引物、试剂盒及其应用
CN113176408B (zh) * 2021-06-02 2022-10-11 四川大学华西医院 一种甲状腺癌预后情况判断的方法
WO2023105119A1 (en) * 2021-12-07 2023-06-15 Sartar Therapeutics Oy Synergistic compositions for use in the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8426804D0 (en) 1984-10-23 1984-11-28 Ciba Geigy Ag Pyridazinones preparations
EP0791584A4 (en) * 1994-11-11 1997-11-19 Nippon Soda Co OPTICALLY ACTIVE CONNECTIONS
US20070172844A1 (en) * 2005-09-28 2007-07-26 University Of South Florida Individualized cancer treatments
WO2007072225A2 (en) * 2005-12-01 2007-06-28 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
EP2970145B1 (en) * 2013-03-11 2020-05-06 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
WO2015077565A1 (en) 2013-11-22 2015-05-28 Board Of Regents, The University Of Texas System Treating cancers with drugs targeting creb3l1
EP3334404A4 (en) 2015-08-13 2019-02-13 The Broad Institute, Inc. COMPOSITIONS AND METHODS FOR DETECTION OF CANCER CELLS EXPRESSING PDE3A OR SLFN12
EP3411037B1 (en) * 2016-02-05 2021-10-20 Bayer Pharma Aktiengesellschaft Compounds, compositions and methods for cancer patient stratification and cancer treatment
WO2018141835A1 (en) * 2017-02-03 2018-08-09 The Broad Institute, Inc. Compounds, compositions and methods for cancer treatment

Also Published As

Publication number Publication date
JP2019508404A (ja) 2019-03-28
CN108883112B (zh) 2022-07-26
CA3013402A1 (en) 2017-08-10
CN108883112A (zh) 2018-11-23
TW201733591A (zh) 2017-10-01
US10966986B2 (en) 2021-04-06
JP7148403B2 (ja) 2022-10-05
WO2017134231A1 (en) 2017-08-10
US20210236504A1 (en) 2021-08-05
EP3411037A1 (en) 2018-12-12
UY37113A (es) 2017-08-31
EP3411037B1 (en) 2021-10-20
CA3234176A1 (en) 2017-08-10
US20190365770A1 (en) 2019-12-05
CN114601837A (zh) 2022-06-10

Similar Documents

Publication Publication Date Title
AR107529A1 (es) Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento
ECSP19042682A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
CL2017003103A1 (es) Compuestos de heteroarilo para la inhibición de cinasa
EA201892229A1 (ru) Замещенные аминопуриновые соединения, содержащие их композиции и способы лечения с их применением
GEP20237506B (en) Pcsk9 antagonist compounds
CL2018000622A1 (es) Acetamida tienodiazepinas de triazol y sus usos relacionados.
EA201891344A1 (ru) Новые агонисты рецептора апелина и способы применения
EA201990615A1 (ru) Пирролобензодиазепиновые конъюгаты
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CU20170029A7 (es) Indazoles sustituidos con bencilo en calidad de inhibidores de bub1, útiles para el tratamiento o profilaxis de una enfermedad hiperproliferativa y/o un trastorno que responde a la inducción de la muerte celular, un procedimiento para la preparación de estos compuestos, y compuestos intermediarios
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
CY1119042T1 (el) Υποκατεστημενες ξανθινες και μεθοδοι χρησης αυτων
UY35500A (es) Indazoles sustituidos con heteroarilo
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
EA201890858A1 (ru) 2,4-дигидроксиникотинамиды как агонисты apj
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
BR112017004953A2 (pt) imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula
CL2019001330A1 (es) Inhibidores de la tirosina quinasa de bruton.
CL2020003354A1 (es) Compuestos
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
BR112017022281A2 (pt) métodos para tratar câncer
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t